Identifying drug-drug interactions (DDIs) is critical for ensuring drug safety and advancing drug development, a topic that has garnered significant research interest. While existing methods have made considerable progress, approaches relying solely on known DDIs face a key challenge when applied to drugs with limited data (e.g., novel and few-shot drugs): insufficient exploration of the space of unlabeled pairwise drugs. To address these issues, we innovatively introduce S2VM, a Selfsupervised Visual pretraining framework for pair-wise Molecules, to fully fuse structural representations and explore the space of drug pairs for DDI prediction. S2VM incorporates the explicit structure and correlations of visual molecules, such as the positional relationships and connectivity between functional substructures. Specifically, we blend the visual fragments of drug pairs into a unified input for joint encoding and then recover molecule-specific visual information for each drug individually.

Specifically, robustness with only ACM loss is 48.38%, the addition of soft-labels improves it to 49.53%, the addition of mixup improves it to 52.29%, and the addition of both of these components make final robustness to 56.65%. Also, note that only soft labels are not enough to transfer robustness in this case, as shown by KDOnly column. This is in line with the observations of Goldblum et al. [4]. A.4.2 Role of Intermediate Features To understand the role of low, mid, and high-level features, we performed experiments on CIFAR-10 by progressively changing blocks used for distillation. For this ablation study, we kept all the standard settings reported in the Section A.1. Our correspondence of blocks and features is as follows: block 2: low-level features; block 3: mid-level features; block 4: high-level features. Please note that block 1 corresponds to the output of the first layer only. Therefore, we do not call it low-level features.

Examining Drug-Drug Interactions (DDIs) is a pivotal element in the process of drug development. DDIs occur when one drug's properties are affected by the inclusion of other drugs. Detecting favorable DDIs has the potential to pave the way for creating and advancing innovative medications applicable in practical settings. However, existing DDI prediction models continue to face challenges related to generalization in extreme cases, robust feature extraction, and real-life application possibilities. We aim to address these challenges by leveraging the effectiveness of context-aware deep graph learning by introducing a novel framework named CADGL. Based on a customized variational graph autoencoder (VGAE), we capture critical structural and physio-chemical information using two context preprocessors for feature extraction from two different perspectives: local neighborhood and molecular context, in a heterogeneous graphical structure. Our customized VGAE consists of a graph encoder, a latent information encoder, and an MLP decoder. CADGL surpasses other state-of-the-art DDI prediction models, excelling in predicting clinically valuable novel DDIs, supported by rigorous case studies.

Most existing methods for predicting drug-drug interactions (DDI) predominantly concentrate on capturing the explicit relationships among drugs, overlooking the valuable implicit correlations present between drug pairs (DPs), which leads to weak predictions. To address this issue, this paper introduces a hierarchical multi-relational graph representation learning (HMGRL) approach. Within the framework of HMGRL, we leverage a wealth of drug-related heterogeneous data sources to construct heterogeneous graphs, where nodes represent drugs and edges denote clear and various associations. The relational graph convolutional network (RGCN) is employed to capture diverse explicit relationships between drugs from these heterogeneous graphs. Additionally, a multi-view differentiable spectral clustering (MVDSC) module is developed to capture multiple valuable implicit correlations between DPs. Within the MVDSC, we utilize multiple DP features to construct graphs, where nodes represent DPs and edges denote different implicit correlations. Subsequently, multiple DP representations are generated through graph cutting, each emphasizing distinct implicit correlations. The graph-cutting strategy enables our HMGRL to identify strongly connected communities of graphs, thereby reducing the fusion of irrelevant features. By combining every representation view of a DP, we create high-level DP representations for predicting DDIs. Two genuine datasets spanning three distinct tasks are adopted to gauge the efficacy of our HMGRL. Experimental outcomes unequivocally indicate that HMGRL surpasses several leading-edge methods in performance.

Relation-aware graph structure embedding is promising for predicting multi-relational drug-drug interactions (DDIs). Typically, most existing methods begin by constructing a multi-relational DDI graph and then learning relation-aware graph structure embeddings (RaGSEs) of drugs from the DDI graph. Nevertheless, most existing approaches are usually limited in learning RaGSEs of new drugs, leading to serious over-fitting when the test DDIs involve such drugs. To alleviate this issue, we propose a novel DDI prediction method based on relation-aware graph structure embedding with co-contrastive learning, RaGSECo. The proposed RaGSECo constructs two heterogeneous drug graphs: a multi-relational DDI graph and a multi-attribute drug-drug similarity (DDS) graph. The two graphs are used respectively for learning and propagating the RaGSEs of drugs, aiming to ensure all drugs, including new ones, can possess effective RaGSEs. Additionally, we present a novel co-contrastive learning module to learn drug-pairs (DPs) representations. This mechanism learns DP representations from two distinct views (interaction and similarity views) and encourages these views to supervise each other collaboratively to obtain more discriminative DP representations. We evaluate the effectiveness of our RaGSECo on three different tasks using two real datasets. The experimental results demonstrate that RaGSECo outperforms existing state-of-the-art prediction methods.

In the last decades, people have been consuming and combining more drugs than before, increasing the number of Drug-Drug Interactions (DDIs). To predict unknown DDIs, recently, studies started incorporating Knowledge Graphs (KGs) since they are able to capture the relationships among entities providing better drug representations than using a single drug property. In this paper, we propose the medicX end-to-end framework that integrates several drug features from public drug repositories into a KG and embeds the nodes in the graph using various translation, factorisation and Neural Network (NN) based KG Embedding (KGE) methods. Ultimately, we use a Machine Learning (ML) algorithm that predicts unknown DDIs. Among the different translation and factorisation-based KGE models, we found that the best performing combination was the ComplEx embedding method with a Long Short-Term Memory (LSTM) network, which obtained an F1-score of 95.19% on a dataset based on the DDIs found in DrugBank version 5.1.8. This score is 5.61% better than the state-of-the-art model DeepDDI. Additionally, we also developed a graph auto-encoder model that uses a Graph Neural Network (GNN), which achieved an F1-score of 91.94%. Consequently, GNNs have demonstrated a stronger ability to mine the underlying semantics of the KG than the ComplEx model, and thus using higher dimension embeddings within the GNN can lead to state-of-the-art performance.

Drug-Drug Interactions (DDIs) may hamper the functionalities of drugs, and in the worst scenario, they may lead to adverse drug reactions (ADRs). Predicting all DDIs is a challenging and critical problem. Most existing computational models integrate drug-centric information from different sources and leverage them as features in machine learning classifiers to predict DDIs. However, these models have a high chance of failure, especially for the new drugs when all the information is not available. This paper proposes a novel Hypergraph Neural Network (HyGNN) model based on only the SMILES string of drugs, available for any drug, for the DDI prediction problem. To capture the drug similarities, we create a hypergraph from drugs' chemical substructures extracted from the SMILES strings. Then, we develop HyGNN consisting of a novel attention-based hypergraph edge encoder to get the representation of drugs as hyperedges and a decoder to predict the interactions between drug pairs. Furthermore, we conduct extensive experiments to evaluate our model and compare it with several state-of-the-art methods. Experimental results demonstrate that our proposed HyGNN model effectively predicts DDIs and impressively outperforms the baselines with a maximum ROC-AUC and PR-AUC of 97.9% and 98.1%, respectively.

Drug-Drug interactions (DDIs) are considered as the unwanted side, causing patients irreparable side effects [1] due to the concurrent consumption of two or more drugs [2-4]. As a fundamental research issue in the field of molecular biology, DDIs has received great attention. The resources of molecular biology, such as research literature, structure diagrams, and interactive genes analyses, have the substantial increments [5-7]. Researchers are facing enormous amount of materials to review, which requires considerable energy to investigate and organize crucial information with difficulty. The achievements of Natural Language Processing (NLP) could accelerate this procedure and improve the reliability for their further research, in the meantime, the linguistics could take advantages of the large, well-curated resources as well [5], benefiting the both groups. Considering the importance of DDIs in humans health, industry and the economy, and the substantial amount of cost and time of experimental approaches [1, 8], it is appropriate to introduce the automatic methodologies into this field. In the work by Zhang et al. [9], they argue that Information Extraction (IE) applications, such as discovering DDIs, must move beyond a scenario where relevant information is coherently and explicitly stated within a single document.

Concomitant administration of drugs can cause drug-drug interactions (DDIs). Some drug combinations are beneficial, but other ones may cause negative effects which are previously unrecorded. Previous works on DDI prediction usually rely on hand-engineered domain knowledge, which is laborious to obtain. In this work, we propose a novel model, Molecular Substructure-Aware Network (MSAN), to effectively predict potential DDIs from molecular structures of drug pairs. We adopt a Transformer-like substructure extraction module to acquire a fixed number of representative vectors that are associated with various substructure patterns of the drug molecule. Then, interaction strength between the two drugs' substructures will be captured by a similarity-based interaction module. We also perform a substructure dropping augmentation before graph encoding to alleviate overfitting. Experimental results from a real-world dataset reveal that our proposed model achieves the state-of-the-art performance. We also show that the predictions of our model are highly interpretable through a case study.

Polypharmacy, defined as the use of multiple drugs together, is a standard treatment method, especially for severe and chronic diseases. However, using multiple drugs together may cause interactions between drugs. Drug-drug interaction (DDI) is the activity that occurs when the impact of one drug changes when combined with another. DDIs may obstruct, increase, or decrease the intended effect of either drug or, in the worst-case scenario, create adverse side effects. While it is critical to detect DDIs on time, it is timeconsuming and expensive to identify them in clinical trials due to their short duration and many possible drug pairs to be considered for testing. As a result, computational methods are needed for predicting DDIs. In this paper, we present a novel heterogeneous graph attention model, HAN-DDI to predict drug-drug interactions. We create a heterogeneous network of drugs with different biological entities. Then, we develop a heterogeneous graph attention network to learn DDIs using relations of drugs with other entities. It consists of an attention-based heterogeneous graph node encoder for obtaining drug node representations and a decoder for predicting drug-drug interactions. Further, we utilize comprehensive experiments to evaluate of our model and to compare it with state-of-the-art models. Experimental results show that our proposed method, HAN-DDI, outperforms the baselines significantly and accurately predicts DDIs, even for new drugs.